Bio-Techne opened at $72.69, in line with its previous close of $72.71. In the last trading session, the stock traded between $72.67 and $72.73. It showed a sideways intraday trend.
An investment of $100 made 5 years ago in Bio-Techne is now worth
$ 55.52
resulting in a loss of
$ 44.48 (44.48%)
Note: Past profits do not guarantee future returns.
Rating from 3 Analysts
Today's Change
$-0.03 (-0.03%)
Day High
$72.73
Day Low
$72.67
Day Open
$72.69
Prev Close
$72.71
Volume
9,67,959
1W Return
0.07%
1M Return
0.43%
3M Return
0.93%
6M Return
39.91%
1Y Return
17.20%
Market Cap ($ Mn)
11,416
PE Ratio
62.37
PB Ratio
5.36
PEG Ratio
10.53
ROE
3.59%
ROCE
4.12%
EPS (TTM)
$0.35
1 Week
0.07%
1 Month
0.43%
3 Months
0.93%
6 Months
39.91%
9 Months
13.61%
Bio-Techne opens Bristol facility to expand GMP manufacturing capacity
New Bristol facility expands GMP small molecule production capacity. Investment strengthens global infrastructure for cell therapy applications. Site complements recent North American investments in St. Paul and Minneapolis. Combined sites support customers from discovery through commercial manufacturing.
22 days agoBio-Techne shareholders approve Merck KGaA acquisition deal
Bio-Techne shareholders approved the acquisition by Merck KGaA on September 23, 2026. Deal closure is expected by late 2026 or early 2027, pending regulatory approvals. Bio-Techne reported over $1.2 billion in net sales for fiscal year 2025.
1mo agoBio-Techne secures SBTi validation for 70% emissions cut target by FY31
SBTi validates Bio-Techne's goal to cut Scope 1 & 2 emissions by 70% by FY31. Market-based Scope 1 and 2 emissions fell 49% YoY in FY26. Over half of electricity consumption now sourced from renewables. First comprehensive Scope 3 emissions inventory completed. Company commits to 81% supplier coverage with science-based targets by FY30.
1mo agoHalper Sadeh probes Bio-Techne's $73 per share sale to Merck KGaA
Halper Sadeh LLC investigates Bio-Techne's proposed sale to Merck KGaA for $73.00 per share in cash. Firm alleges potential breach of fiduciary duties and failure to secure best possible price for shareholders. Concerns raised about insider financial benefits and terms limiting superior competing offers. Shareholders can contact the firm on a contingent fee basis to discuss their rights.
2mo agoBio-Techne corrects dividend record date to August 24
Bio-Techne Corporation corrected its dividend announcement to set the shareholder of record date as August 24, 2026, instead of August 17. The $0.08 per share dividend for Q2FY27 will be paid on August 28, 2026. All other terms remain unchanged.
2mo agoBio-Techne Q4 Results: Sales rise 1.33% YoY, beat estimates
Bio-Techne delivered Q4 adjusted EPS of $0.52, meeting estimates, while sales of $321.191 million beat forecasts by 2.07%. Revenue grew 1.33% YoY, though EPS declined 1.89% from the prior year's $0.53.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $540.00 | +1.95% | $1,36,868.94M | 31.55 | |
| $61.07 | +2.12% | $1,31,639.87M | 14.39 | |
| $222.76 | +4.01% | $88,933.81M | - | |
| $818.77 | +0.68% | $82,808.76M | 19.64 | |
| $897.85 | +0.68% | $56,462.20M | 38.99 | |
| $371.56 | -0.48% | $40,792.43M | 65.60 | |
| $190.27 | +0.82% | $40,781.71M | - | |
| $56.49 | -1.40% | $35,253.15M | 26.24 | |
| $65.93 | +1.71% | $29,357.11M | 32.37 | |
| $37.52 | +1.10% | $27,101.56M | - | |
| $111.59 | +15.07% | $24,369.25M | - | |
| $116.80 | -0.06% | $23,675.13M | 15.85 |
An investment of $100 made 5 years ago in Bio-Techne is now worth
$ 55.52
resulting in a loss of
$ 44.48 (44.48%)
Note: Past profits do not guarantee future returns.
